Skip to main content

Table 3 Overall response

From: Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer

Best response

Trifluridine/tipiracil plus bevacizumab group

Trifluridine/tipiracil monotherapy group

P

N = 60

%

N = 66

%

PR

3

5.0

1

1.5

 

SD

29

48.3

29

43.9

PD

25

41.7

34

51.5

NE

3

5.0

2

3.0

ORR

3

5.0

1

1.5

0.346

DCR

32

53.3

30

45.5

0.476

  1. DCR disease control rate, NE not evaluated, ORR overall response rate, PD progressive disease, PR partial response, SD stable disease